Market News / Story
OABI — xPloration scales commercialization as new platforms and royalties mature
Quartr ·
Quartr reports: Expanded xPloration availability and the OmniTides peptide platform broaden commercialization and partnering opportunities. FY2026 guidance remains $32M–$36M in revenue and $51M–$55M in cash operating expenses, with cash flow expected near breakeven. Based on OmniAb, Inc. [OABI] Investor And Anlayst Day 2026 Audio Transcript — Oct. 6 2026 This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.